Results 11 to 20 of about 276,512 (289)
Journal of Travel Medicine, 1995 Hepatitis A is a self-limiting inflammation of the liver, which is caused by the hepatitis A virus. The infection is rare in industrialized countries but highly endemic in many developing countries. Until recently, only short-lived protection was possible using human immunoglobulin, but inactivated hepatitis A vaccines have now become available.
, D'Hondt, , Beecham
+11 more sources
Brazilian Protocol for Sexually Transmitted Infections 2020: viral hepatitis
Revista da Sociedade Brasileira de Medicina Tropical, 2021 This article discusses viral hepatitis, a theme addressed by the Clinical Protocol and Therapeutic Guidelines to Comprehensive Care for People with Sexually Transmitted Infections and, more precisely, by the Clinical Protocols and Therapeutic Guidelines ...
Geraldo Duarte +4 more
doaj +1 more source
HBV Vaccines: Advances and Development
Vaccines, 2023 Hepatitis B virus (HBV) infection is a global public health problem that is closely related to liver cirrhosis and hepatocellular carcinoma (HCC). The prevalence of acute and chronic HBV infection, liver cirrhosis, and HCC has significantly decreased as ...
Faisal Mahmood +9 more
doaj +1 more source
Human Vaccines & Immunotherapeutics, 2020 Hepatitis A is an important public health issue worldwide. Hepatitis A vaccine (HepA) was first licensed in 1992. Both inactivated HepA (HepA-I) and live attenuated HepA (HepA-L) are highly immunogenic and well tolerated, and immune protection postvaccination can persist for at least 20 y.
openaire +3 more sources
Health disparities in chronic liver disease
Hepatology, EarlyView., 2022 Abstract The syndemic of hazardous alcohol consumption, opioid use, and obesity has led to important changes in liver disease epidemiology that have exacerbated health disparities. Health disparities occur when plausibly avoidable health differences are experienced by socially disadvantaged populations.
Ani Kardashian +3 more
wiley +1 more source
Identification of novel neutralizing determinants for protection against HCV
Hepatology, EarlyView., 2022 Identification of novel neutralizing determinants for protection against hepatitis C virus. Abstract Background and Aims HCV evasion of neutralizing antibodies (nAb) results in viral persistence and poses challenges to the development of an urgently needed vaccine.
Garazi P. Alzua +12 more
wiley +1 more source
Memorias do Instituto Oswaldo Cruz, 2012 Age-related seroprevalence studies that have been conducted in Brazil have indicated a transition from a high to a medium endemicity of hepatitis A virus (HAV) infection in the population.
Claudia Lamarca Vitral +15 more
doaj +1 more source
Human Vaccines & Immunotherapeutics, 2016 The WHO recommends integration of universal mass vaccination (UMV) against hepatitis A virus (HAV) in national immunization schedules for children aged ≥1 year, if justified on the basis of acute HAV incidence, declining endemicity from high to ...
A. Stuurman +4 more
semanticscholar +1 more source
Leveraging corona virus disease 2019 vaccination to promote hepatitis C screening
Hepatology Communications, EarlyView., 2022 Abstract Health care initiatives, such as hepatitis C virus (HCV) screening, have been greatly overshadowed by the corona virus disease 2019 (COVID‐19) pandemic. However, COVID‐19 vaccination programs also provide an opportunity to engage with a high volume of people in a health care setting.
Aaron Vanderhoff +17 more
wiley +1 more source
Frontiers in Cellular and Infection Microbiology, 2021 ObjectivesTo compare the safety, immunogenicity, and immune persistence of hepatitis A (HA) vaccines between HBs-Ag-positive and -negative participants.Method9000 participants were enrolled in the phase IV study of live attenuated HA (HA-L) or ...
Xiaodan Wang +49 more
doaj +1 more source